[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Comenius University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":199},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,78,110,138,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100633147","virtual-buddy-movement-therapy-for-psychomotor-and-social-development-in-pediatric-oncology-patients-in-remission-100633147",false,"NCT07522905","Virtual Buddy Movement Therapy for Psychomotor and Social Development in Pediatric Oncology Patients in Remission","The Impact of a 12-week Virtual Buddy-movement Therapy on the Psychomotor and Social Development of Pediatric Oncology Patients in Remission","Inclusion Criteria:\n\n* Age: 5-12 years\n* Diagnosis: acute lymphoblastic leukemia in complete remission\n* First-line treatment of acute lymphoblastic leukemia according to the treatment protocol\n* BUDDY - a healthy friend aged 5-12 years\n\nExclusion Criteria:\n\n* Participation in the movement program less than 80%","ALL","5 Years","12 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","Acute lymphoblastic leukemia is the most common type of cancer in children diagnosed between the ages of two and five. After cancer treatment, children suffer from fatigue and exhaustion, and thus a decrease in daily physical activity. In addition, lack of physical activity and sports causes a decrease in strength and mobility and affects coordination of movements, proprioceptive perception and balance, which can lead to the occurrence of many injuries. In addition, physical inactivity in children who have survived cancer increases the risk of cardiovascular diseases or causes overweight and obesity. In addition, the separation of children with cancer from their peers harms social, emotional, physical and school indicators of quality of life. The aim of the project is to determine the impact of 12 weeks of buddy-movement therapy on the psychomotor and social development of pediatric cancer patients in remission. The investigators expect a significant improvement in the motor skills of pediatric oncology patients in remission, specifically in fine and gross motor skills, in coordination of both hands, in body coordination, in strength and dexterity. The investigators also assume that after the introduction of 12-week buddy-movement therapy, there will be a significant improvement in the quality of life of pediatric oncology patients in remission, specifically in emotional functioning, in social functioning, in physical functioning and in school functioning. Furthermore, it is anticipated that after the introduction of 12-week buddy-movement therapy, the study will notice significant differences in motor skills between the experimental and control groups. It is also assumed that after the introduction of 12-week buddy-movement therapy, significant differences in quality of life between the experimental and control groups will be observed. The research will involve pediatric oncology patients in remission aged 5 to 12 years with acute lymphoblastic leukemia - ALL, who are treated at the Department of Pediatric Hematology and Oncology of the National Institute of Children's Diseases (NÚDCH). The research participants will undergo an entry and exit examination, including body mass index (BMI; kg\u002Fm\\^2) calculated from weight (kg), height (m), waist circumference (cm), hip circumference (cm), psychomotor examination using the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition, and quality of life measured by the Pediatric Quality of Life Inventory. They will be divided into a control and experimental group, with the experimental group undergoing a 12-week Buddy-movement therapy focused on the development of psychomotor skills and socialization of participants using Buddy peer support.",[27],"Precursor Cell Lymphoblastic Leukemia-Lymphoma",[29,30,31,32,33,34],"Pediatric Cancer Survivors","Acute Lymphoblastic Leukemia","Movement Therapy","Psychomotor development","Quality of life","BUDDY","RECRUITING","2026-05-01",{"date":38,"type":39},"2026-05-07","ACTUAL",{"date":41,"type":39},"2026-04-07",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"Comenius University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100599161","the-effect-of-distal-versus-proximal-ipack-on-pain-after-total-knee-arthroplasty-100599161","NCT07080892","The Effect of Distal Versus Proximal iPACK on Pain After Total Knee Arthroplasty","The Effect of Distal Versus Proximal Approach to the Interspace Between the Popliteal Artery and the Posterior Capsule of the Knee (iPACK) on Pain After Total Knee Arthroplasty","eDIPACK","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Patients undergoing primary unilateral total knee arthroplasty (TKA) for osteoarthritis\n* Ability to understand and sign informed consent\n* American Society of Anesthesiologists (ASA) classification I-III\n* Ability to cooperate and participate in postoperative pain assessments (e.g., VAS)\n\nExclusion Criteria:\n\n* Refusal to participate or failure to sign informed consent\n* Bilateral or revision TKA\n* Partial or unicondylar knee replacement\n* Severe knee deformity (flexion, varus, or valgus \\>30°)\n* Diagnosis other than osteoarthritis (e.g., rheumatoid arthritis, septic arthritis, post-traumatic arthritis)\n* Allergy to local anesthetics or any medications used in the study\n* Contraindications to regional anesthesia (e.g., infection at the injection site, coagulopathy, therapeutic anticoagulation)\n* BMI \\> 40 kg\u002Fm²\n* Severe renal impairment (KDIGO stage G4 or higher) or liver failure (Child-Pugh score ≥ 10)\n* Prior surgery or vascular procedure on the femoral vessels of the operated limb\n* Language barrier or inability to assess pain using the VAS\n* Planned outpatient (same-day discharge) procedure","18 Years","80 Years",{"count":59,"type":21},120,[24],"Total knee arthroplasty (TKA) often results in significant postoperative pain, which can hinder recovery despite advances in surgical and anesthetic techniques. Traditional pain management methods like femoral nerve blocks may impair motor function, delaying rehabilitation. The iPACK block, targeting the posterior knee without affecting motor control, offers a promising alternative. This study aims to compare the effectiveness of two iPACK block approaches-proximal (at the distal femoral shaft) and distal (between the femoral condyles)-in managing postoperative pain in TKA patients. In a double-blind, randomized controlled trial with 120 participants, pain scores, opioid use, and time to rescue analgesia will be assessed. The hypothesis is that the distal iPACK block provides superior pain relief, potentially improving patient outcomes and recovery.",[63],"Postoperative Pain Following Knee Arthroplasty",[65,66,67,68,69],"pain","postoperative pain","arthroplasty","peripheral nerve block","iPACK","2026-02-02",{"date":72,"type":39},"2026-02-04",{"date":74,"type":39},"2025-02-12",{"date":76,"type":21},"2027-05-30",{"name":45,"class":46},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":86,"enrollmentInfo":87,"targetDuration":89,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":47},"100620953","cognitive-function-in-obstructive-sleep-apnea-100620953","NCT07364318","Cognitive Function in Obstructive Sleep Apnea","Cognitive Function and Pathophysiological Mechanisms in Adults With Obstructive Sleep Apnea: Long-term Impact of Positive Airway Pressure Therapy","CUFM1DN","Inclusion Criteria:\n\n1. Informed consent.\n2. Age 18 - 65 years.\n3. Newly diagnosed OSA according to the criteria of the American Academy of Sleep Medicine Guidelines (overnight PSG with an AHI ≥5 events per hour, hypopneas defined by ≥ 10 seconds of airflow reduction accompanied by ≥ 3% desaturation or an arousal).\n4. Able to accomplish relevant tests and follow-up.\n\nExclusion Criteria:\n\n1. History of any chronic disease other than overweight and obesity.\n2. Severe psychiatric condition that could affect cognitive functions.\n3. Chronic use of medication or nicotine that may affect the study results.\n4. Prior neuropsychological assessment less than 6 months before the start of the research.\n5. Prior therapy for OSA (i.e., CPAP, upper airway surgery, or oral appliance).\n6. Motor or sensory deficits that would significantly complicate test administration.\n7. Patients who do not have Slovak as their native language actively used in daily communication.\n8. Considered by the study team as not suitable for enrollment based on clinical judgment.","65 Years",{"count":88,"type":21},30,"12 Months","OBSERVATIONAL","Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and has been increasingly recognized as a contributor to cognitive decline and a potential risk factor for neurodegeneration. Previous studies have identified several associated comorbidities, including vascular dysfunction, metabolic alterations, and neuroinflammatory changes. However, the impact and underlying interplay of these pathophysiological mechanisms remain poorly understood due to the lack of integrated, multidimensional assessment. This prospective, observational, longitudinal cohort study aims to investigate cognition and OSA-related physiological and pathophysiological processes in 100 adults newly diagnosed with OSA, who have no history of chronic diseases (except for overweight and obesity) and are not receiving chronic medication. A subgroup of patients with moderate to severe OSA indicated for positive airway pressure (PAP) therapy will be followed to evaluate its long-term effects on cognitive function and related mechanisms. All participants will undergo polysomnography (PSG), comprehensive neuropsychological assessment, brain MRI with volumetric analysis, biomarker profiling from blood and saliva, and evaluation of endothelial function, baroreflex sensitivity, and gut microbiome composition at baseline and after 12 months. PAP adherence will be continuously monitored. The primary objective of this study is to characterize the profile of cognitive impairment associated with OSA. Secondary exploratory analyses will focus on factors contributing to neurocognitive dysfunction in OSA.",[93,94],"OSA - Obstructive Sleep Apnea","Cognitive Functions",[96,97,98,99,100,101,102],"Cognitive Function","Positive Airway Pressure Therapy","Obstructive Sleep Apnea","Neuroimaging","Biomarkers","Vascular Changes","Metabolic Changes","2026-01-15",{"date":105,"type":39},"2026-01-23",{"date":107,"type":39},"2024-11-01",{"date":43,"type":21},{"name":45,"class":46},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":16,"minAge":56,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":47},"100580846","prospective-evaluation-of-diagnostic-performance-of-pantum-detect-test-in-adult-patients-with-suspected-or-confirmed-macroscopic-solid-pre-malignant-or-malignant-lesions-referred-to-fludeoxyglucose-18f-petct-and-in-adult-healthy-population-100580846","NCT06842615","Prospective Evaluation of Diagnostic Performance of PanTum Detect Test in Adult Patients With Suspected or Confirmed Macroscopic Solid Pre-malignant or Malignant Lesion(s) Referred to Fludeoxyglucose (18F) PET\u002FCT and in Adult Healthy Population","PanTumPET","Inclusion Criteria:\n\nTo be eligible to participate in this trial, an individual must meet all the following criteria:\n\nGroup A\n\n* Age 18-88 years at inclusion (Man, Woman)\n* Suspected or confirmed macroscopic solid pre-malignant or malignant lesion(s)\n* Availability of result of FDG PET\u002FCT performed -30 to-15 days or up to +30 days from trial intervention and performed as a standard of care\n* Willingness to undergo trial intervention\n* Signed informed consent\n* Absence of any of exclusion criteria Group B\n* Age 18-88 years at inclusion (Man, Woman)\n* Considered as free of pre-malignant or malignant lesion(s) at the time of inclusion\n* Willingness to undergo trial intervention\n* Signed informed consent\n* Absence of any of exclusion criteria\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this trial: For Group A and B\n\n1. Acute Illness, Organ Transplantation, Surgeries, and injuries are an exclusion criteria: e.g. bone fracture, deep cut (deeper 0.5 cm and\u002For larger than 1 cm), abrasion (greater than 5 cm in diameter), open wound, contusion, torn ligaments, blood in the stool, blood in the urine. After successful recovery the waiting period must be 8 weeks.\n2. Medication: Any treatment or activity that could impact the immune system must be considered as an exclusion criteria.These includes.\n\n   1. Steroid-, chemo-, radio therapy in last 8 weeks\n   2. Immunesuppression using following active ingredients; Methotrexate, Cyclosporine, Azathioprine, Tacrolimus, Mycophenolate, Rapamycin, Sirolimus, Mycophenolat-Mofetil in last 8 weeks.\n   3. Granulocyte-Macrophage Colony-Stimulating Factor (GM-SCF); Molgramostim, Sargramostim in last 8 weeks o Amygdalin (Vitamin B17) in last 4 weeks\n   4. Immune modulation using Corticosteroids, Glucocorticoids and Colchicine (Cortison\u002Fhydrocortisone \\>5 mg\u002Fday, Budesonid \\>5 mg\u002Fday) in last 4 weeks\n   5. Non-Steroidal anti-inflammatory drugs (NSAIDs) \\& CGRP including in last 2 weeks. An occasional use of Ibuprofen, Paracetamol and Aspirin is not an exclusion criteria.\n   6. Antibiotics and Antifungals in last 2 weeks\n3. Vaccination: any vaccination in last 4 weeks.\n4. Infection: Acute Bacterial, Viral infection and Fungal infection in last 2 weeks.\n5. Imaging Investigation using contrast medium in last 2 weeks.\n6. Dialysis on the day of blood draw.\n7. Genetic disorder such as thrombocytopenia may leads to rejection of test due to reduced amount of Blood Cells.\n\nFor Group B only:\n\n1\\. Previous and Current Cancer: In case of previously diagnosed and successfully treated Tumour \\& cancer, the PanTum Detect test should be done 5 years after the successful treatment \\& cure. This applies to all kind of Tumour and Cancers. all currently ongoing cancer treatments and newly diagnosed cancer including ongoing diagnostic procedures are an exclusion criterion",true,"88 Years",{"count":120,"type":21},134,[24],"This prospective phase II trial aims to evaluate the diagnostic performance of multi-cancer epitope diagnosis in monocyte (EDIM) based blood test PanTum detect test for early detection of individuals with pre-malignant or malignant lesion(s).\n\nThe intervention in this trial is the PanTum detect test performed in two parallel groups of participants:\n\nGroup A:\n\nAdult persons\n\n* with suspected or confirmed macroscopic solid pre-malignant or malignant lesion(s) referred to FDG PET\u002FCT\n* meeting the inclusion criteria and not-meeting the exclusion criteria\n* Expected number of participants: 67\n\nGroup B:\n\nHealthy adult persons\n\n* meeting inclusion criteria meeting the inclusion criteria and not-meeting the exclusion criteria\n* Expected number of participants: 67 Control method: uncontrolled\n\nType of trial: evaluation of diagnostic performance of a diagnostic test with following Primary and Secondary objectives:\n\nPrimary Objective\n\n1\\. To evaluate the sensitivity and specificity of PanTum Detect test in identification of individuals bearing macroscopic solid pre-malignant or malignant lesion(s) Secondary Objectives\n\n1. To evaluate the positive and negative predictive value of PanTum Detect test in identification of individuals bearing macroscopic solid pre-malignant or malignant lesion(s)\n2. To assess the concordance of result of PanTum Detect test with result of FDG PET\u002FCT for macroscopic solid pre-malignant or malignant lesion(s)\n3. To analyse the most frequent causes of false results of PanTum Detect test\n4. To analyze the concordance rate of PanTum Detect test No1 and No2\n5. To refine the interpretation criteria of PanTum Detect test\n6. To analyse the subject´s willingness to participate on the trial\n7. To analyse the subject´s experience with participation on the trial",[124,125],"Pre-malignant","Malignant",[127,128,129,130],"macroscopic","solid lesion","pre-malignant","malignant lesion",{"date":132,"type":39},"2026-01-16",{"date":134,"type":39},"2025-05-25",{"date":136,"type":21},"2028-03-31",{"name":45,"class":46},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":47},"100537693","stress-reducing-intervention-in-patients-with-colorectal-and-breast-cancer-100537693","NCT06281145","Stress-Reducing Intervention in Patients With Colorectal and Breast Cancer","A Study on Therapeutic Potential of Stress-Reducing Intervention in Patients With Solid Tumors","SRI-BrCa_CRC","Inclusion Criteria:\n\n1. Patients older than 18 years.\n2. Pathologically confirmed breast cancer indicated for neoadjuvant systemic treatment or colon cancer after curative surgery indicated for adjuvant systemic treatment.\n3. Adequate renal functions: measured or calculated (by Cockcroft formula) creatinine clearance \\> 60 ml\u002Fmin.\n4. Absolute granulocytes count ≥ 1,500\u002Fmm3, platelets ≥ 100,000 mm3, bilirubin ≤ 1.5x the upper limit of normal value.\n5. Adequate liver functions defined by AST (Aspartate aminotransferase) and ALT (Alanine transaminase) ≤ 3xUNL (upper normal of limit).\n6. Basic computer skills of patient or his family member.\n7. Signed informed consent.\n\nExclusion Criteria:\n\n1. Previous chemotherapy.\n2. Previous malignancy, except for basal-cell carcinoma of the skin within last 5 years.\n3. Patients with know primary immunodeficiency and patients infected by the Human Immunodeficiency Virus (HIV).\n4. Patient receiving long term corticosteroid treatment, anti-arrhythmic drugs and opioids who can not withdraw the treatment for the period of application of the heart rate variability (HRV) biofeedback training.\n5. Patients with diabetes mellitus, cardiac arrhythmia, cardiac pacemaker implant.\n6. Patients who do not fit inclusion criteria.",{"count":147,"type":21},100,[24],"The goal of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in 2 cohorts of patients. Cohort A will evaluate the effect of the addition of HRV BI in patients with breast cancer treated in the neoadjuvant setting (vs. standard of care alone, SOC) followed by local therapy (surgery +\u002F-radiotherapy). Cohort B will evaluate the effect of the addition of HRV BI in patients with colon cancer after surgery in the adjuvant setting (vs. standard of care alone, SOC).",[151,152],"Breast Cancer","Colon Cancer",[152,154,155,156,157,158,159,160,161,162,163,164],"Invasive Breast Cancer","Neoadjuvant Chemotherapy","Standard of Care","Inflammation","Stress","Telemedicine","Circadian rhythms","Sleep Quality","Quality of Life","Autonomic Nervous System","Heart-Rate Variability","2024-02-20",{"date":167,"type":39},"2024-02-28",{"date":169,"type":21},"2024-03-15",{"date":171,"type":21},"2029-03-15",{"name":45,"class":46},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":47},"100536800","stress-reducing-intervention-in-urothelial-carcinoma-100536800","NCT06269536","Stress-reducing Intervention in Urothelial Carcinoma","A Study on Therapeutic Potential of Stress-reducing Intervention in Patients With Urothelial Carcinoma","Inclusion criteria:\n\n1. Patients older than 18 years.\n2. Evidence of muscle-infiltrating urothelial bladder carcinoma (including variants) by biopsy.\n3. No prior chemotherapy.\n4. No previous malignancy, except for basal-cell carcinoma of the skin within last 5 years.\n5. Adequate renal functions: measured or calculated (by Cockcroft formula) creatinine clearance \\> 60 ml\u002Fmin.\n6. Absolute granulocytes count 1,500\u002Fmm3 or higher, platelets 100,000\u002Fmm3 or higher, bilirubin 1.5x the upper limit of normal value and lower.\n7. Adequate liver functions.\n8. Basic computer skills.\n9. Signed informed consent.\n\nExclusion criteria:\n\n1. Diabetes mellitus with symptomatic neuropathy.\n2. Using antiarrhythmic drugs, opiates and\u002For antidepressants.\n3. Implanted permanent pacemaker (PPM).\n4. Human Immunodeficiency Virus (HIV) infection.\n5. Not fitting inclusion criteria.",{"count":181,"type":21},50,[24],"The aim of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in patients with muscle-infiltrating bladder carcinoma (MIBC) treated with chemotherapy based on cisplatin in neoadjuvant setting followed by local therapy (standard of care, SOC) compared to SOC alone.",[185],"Bladder Cancer",[187,155,156,164,188,157,162,94,189,190,161],"Muscle-Infiltrating Urothelial Carcinoma","Biofeedback Intervention","Salivary Cortisol Slopes","Circadian Rhythms","2024-02-13",{"date":193,"type":39},"2024-02-21",{"date":195,"type":21},"2024-02-15",{"date":197,"type":21},"2029-02-15",{"name":45,"class":46},""]